RALLIS CHRIS A 4
4 · FENNEC PHARMACEUTICALS INC. · Filed Oct 14, 2025
Insider Transaction Report
Form 4
RALLIS CHRIS A
Director
Transactions
- Sale
Common Shares
2025-10-10$9.24/sh−1,775$16,401→ 57,079 total - Exercise/Conversion
Common Shares
2025-10-10$1.23/sh+4,062$4,996→ 58,854 total
Footnotes (3)
- [F1]Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on May 19, 2025.
- [F2]Shares sold to satisfy tax obligation on option exercise.
- [F3]Represents options exercised pursuant to a 10b5-1 plan adopted on May 19, 2025.